Group 1 - Jinli Permanent Magnet expects a net profit of 505 million to 550 million yuan for the first three quarters of 2025, representing a year-on-year increase of 157% to 179% [1] - Guangdong Mingzhu anticipates a net profit of 215 million to 263 million yuan for the first three quarters of 2025, with a year-on-year growth of 858.45% to 1,071.44% [1] - Guangda Special Materials forecasts a net profit of approximately 248 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of about 213.92% [2] Group 2 - Taotao Vehicle expects a net profit of 580 million to 620 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 92.46% to 105.73% [2] - Dongfang Wealth has set the initial transfer price at 24.40 yuan per share, which is an 8.9% discount from the closing price [3] - Ganfeng Lithium has established a complete integrated layout for solid-state batteries and possesses commercialization capabilities [3] Group 3 - Huahai Pharmaceutical's subsidiary has received acceptance for the marketing authorization application of a targeted IL-36R antibody, which is the first of its kind developed in China [4][5] - Xingqi Eye Medicine has obtained clinical trial approval for SQ-129, a sustained-release injection for treating diabetic macular edema [6] - Muyuan Foods has raised its forecast for piglet output in 2025 to a range of 12 million to 14.5 million heads [6] Group 4 - Tianhe Magnetic Materials plans to invest 900 million yuan in high-performance rare earth permanent magnet projects [6] - Qianli Technology reported a significant increase in new energy vehicle production, with 4,282 units produced in September 2025, a year-on-year increase of 975.88% [6] - Yongzhen Co. has signed a strategic cooperation agreement with BYD to provide aluminum alloy components for energy storage [6] Group 5 - Xingye Silver Tin's controlling shareholder has completed its restructuring plan without changing the control of the listed company [7] - Jiangxi Copper has experienced significant price increases in its main products, copper cathodes and gold [7] - Saisir has signed a framework agreement with ByteDance's Volcano Engine for collaboration in embodied intelligence [8] Group 6 - Luoyang Molybdenum's production and operational activities remain normal, with no significant fluctuations in production costs or sales [8] - Tongling Nonferrous Metals has reported significant price increases in its main products, copper cathodes and gold, with low processing fees for copper concentrate [8] - New Yisheng has set the initial transfer price at 328 yuan per share, reflecting a 6.6% discount from the closing price [9] Group 7 - Lichong Group has signed a strategic cooperation agreement with Weijing Intelligent to extend its business into humanoid robotics [10] - Poly Development plans to transfer 4.512 billion shares to Poly Group, making it the controlling shareholder [10] - Huajian Group's executives plan to collectively reduce their holdings by 1.05 million shares [10][11]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd. (referred to as "Huatai"), has received a notice of acceptance from the National Medical Products Administration for the registration application of HB0034 injection, aimed at treating adult generalized pustular psoriasis (GPP) flare-ups [1] Group 1 - HB0034 is the first domestically developed innovative anti-IL-36R antibody in China, which can exert anti-inflammatory biological effects by inhibiting the IL-36 pathway [1] - Currently, there are no domestically developed targeted IL-36R antibodies approved for marketing globally [1] - Clinical research results indicate that compared to placebo, a single intravenous administration of HB0034 leads to significant clearance of skin pustules in GPP patients within one week, achieving the predefined primary research endpoint [1] Group 2 - The safety profile of HB0034 is favorable, with no new safety signals identified during the studies [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd. (referred to as "Huatai"), has received the acceptance notice for the domestic production drug registration application of HB0034 injection from the National Medical Products Administration. This drug is aimed at treating adult generalized pustular psoriasis (GPP) [1] Group 1 - HB0034 is the first domestically developed innovative anti-IL-36R antibody in China, which can exert anti-inflammatory biological effects by inhibiting the IL-36 pathway [1] - The drug has shown significant skin pustule clearance in GPP patients one week after a single intravenous administration compared to placebo, achieving the predefined primary research endpoint [1] - Safety results for HB0034 have been favorable, with no new safety signals identified [1]

Core Viewpoint - The company has received a notice of acceptance for the production registration application of HB0034, a targeted IL-36R antibody, which is the first domestically developed innovative drug for treating generalized pustular psoriasis (GPP) in adults [1] Group 1: Product Development - The drug HB0034 is designed to treat adult patients with GPP and is the first self-developed targeted IL-36R antibody approved for production in China [1] - The drug works by inhibiting the IL-36 pathway to exert anti-inflammatory biological effects [1] Group 2: Clinical Results - Research analysis indicates that compared to a placebo, a single intravenous administration of HB0034 leads to significant clearance of skin pustules in GPP patients within one week, achieving the predefined primary research endpoint [1] - The safety profile of HB0034 is reported to be good, with no new safety signals identified [1]

本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600521 证券简称：华海药业 公告编号：临 2025-106 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 可转换公司债券转股结果暨股份变动公告 重要内容提示： 累计转股情况：浙江华海药业股份有限公司可转换公司债券（以下简称 "华海转债"）于2021年5月6日开始转股，截至2025年9月30日，累计共有194,000 元华海转债转为公司股份，因转股形成的股份数量为5,665股，占华海转债转股 前公司已发行股份总额的0.00039%。 未转股可转债情况：截至2025年9月30日，除已回售的可转债外（期间 公司可转债回售金额为1,000元），尚未转股的华海转债金额为1,842,405,000元， 占华海转债发行总额的99.9894%。 本季度转股情况：自2025年7月1日至2025年9月30日期间，华海转债合计 共有12,000元转为公司股份，因转股形成的股份数量为361股，占华海转债转股 前公司已发行股份总额的0.000025%。 一、可 ...

| 股票简称：华海药业 股票代码：600521 | 公告编号：临 | 号 2025-105 | | --- | --- | --- | | 债券简称：华海转债 债券代码：110076 | | | 浙江华海药业股份有限公司 关于子公司药品上市许可申请获得受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）下属子 公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）收到国家药品监督管 理局（以下简称"国家药监局"）签发的瑞西奇拜单抗（研发代号为：HB0034）注射 液境内生产药品注册上市许可申请的《受理通知书》。现将相关情况公告如下： 一、药物基本情况 受理号：CXSS2500106 申请事项：境内生产药品注册上市许可 申请人：上海华奥泰生物药业股份有限公司 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 规格：120mg（2ml）/瓶 申报适应症：用于治疗成人泛发性脓疱型银屑病（GPP）发作 注册分类：治疗用生物制品 1 类 申请人：上海华奥泰生 ...

Core Viewpoint - Huahai Pharmaceutical (600521) announced that its subsidiary, Huaotai, received the acceptance notice for the drug registration application of HB0034 injection from the National Medical Products Administration, which is intended for the treatment of adult generalized pustular psoriasis (GPP) flare-ups [1] Company Summary - Huahai Pharmaceutical's subsidiary, Huaotai, is advancing in the pharmaceutical market with the development of HB0034 injection [1] - The drug is specifically aimed at treating a significant dermatological condition, indicating potential market demand and therapeutic relevance [1] Industry Summary - The approval process for new drug applications is critical in the pharmaceutical industry, reflecting regulatory compliance and the potential for market entry [1] - The treatment of generalized pustular psoriasis represents a niche but important segment within dermatological therapies, highlighting ongoing innovation in this area [1]

Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].

Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 15.77% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 29, Huahai Pharmaceutical's stock price was 20.40 yuan per share, with a market capitalization of 30.544 billion yuan [1]. - The stock has seen significant trading activity, with a net inflow of 363,300 yuan from main funds and notable buying and selling volumes over recent days [1]. Shareholder Information - As of September 19, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - Major shareholders include China Europe Medical Health Mixed A, which increased its holdings by 12.234 million shares, and Southern CSI 500 ETF, which also saw an increase in holdings [3].

Core Viewpoint - The announcement of a 100% tariff on all branded or patented pharmaceuticals imported into the U.S. starting October 1 has caused significant turmoil in the global pharmaceutical market, particularly affecting major European and Asian pharmaceutical companies [1][3][5]. Tariff Policy Details - The tariff specifically targets branded or patented pharmaceuticals, exempting generics, biosimilars, and raw materials [5][6]. - The policy follows a series of investigations and threats from the U.S. government regarding drug imports, with the final tariff being less severe than initially proposed [3][5]. - Major pharmaceutical stocks, particularly in Europe and Asia, experienced notable declines following the announcement, with companies like Novo Nordisk and GlaxoSmithKline seeing drops of 3.1% and 1.1% respectively [3][5]. Impact on Global Pharmaceutical Companies - U.S. pharmaceutical companies, such as Pfizer and Merck, are expected to benefit from the tariff as it may enhance their market share domestically [5][6]. - Companies are responding by increasing investments in U.S. production capabilities, with Johnson & Johnson planning to invest $55 billion over five years to bolster local manufacturing [6][7]. - The cost implications of the tariff are significant, potentially doubling the cost of imported drugs, which could lead to increased healthcare costs in the U.S. [5][6]. Response from Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are likely to be less affected due to their focus on generic drugs and raw materials, which are not subject to the new tariffs [2][9]. - The majority of Chinese exports to the U.S. consist of generics (over 60%) and raw materials (approximately 25%), with patented drugs making up less than 15% [9][10]. - Chinese companies like Huahai Pharmaceutical and Haisco Pharmaceutical are positioned to avoid tariff impacts by focusing on generics and utilizing licensing agreements for any innovative drugs [10][11]. Opportunities for Chinese Pharmaceutical Industry - The tariff situation may create unexpected growth opportunities for Chinese pharmaceutical companies as Western firms are forced to relocate production to the U.S., potentially diminishing their competitiveness in other markets [11][12]. - The restructuring of the global pharmaceutical supply chain could lead to increased demand for outsourcing services, benefiting Chinese contract research organizations (CROs) [11][12]. - Analysts suggest that the actual impact of the tariff on Chinese pharmaceutical stocks is minimal, with upcoming healthcare negotiations and data releases potentially serving as catalysts for recovery [11][12].